End-of-day quote
INDONESIA S.E.
03:30:00 29/04/2024 am IST
|
5-day change
|
1st Jan Change
|
725
IDR
|
+2.84%
|
|
+2.11%
|
+38.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,89,77,560
|
2,39,63,821
|
2,59,47,816
|
2,26,50,000
|
1,57,50,000
|
2,17,50,000
|
-
|
-
|
Enterprise Value (EV)
2 |
18,113
|
22,939
|
24,868
|
21,727
|
14,929
|
20,772
|
20,713
|
20,597
|
P/E ratio
|
23.5
x
|
25.7
x
|
20.5
x
|
20.5
x
|
16.6
x
|
19.3
x
|
18.7
x
|
16.8
x
|
Yield
|
3.84%
|
3.9%
|
3.95%
|
-
|
-
|
4.53%
|
5.06%
|
5.61%
|
Capitalization / Revenue
|
6.19
x
|
7.18
x
|
6.45
x
|
5.86
x
|
4.42
x
|
5.53
x
|
5.22
x
|
4.75
x
|
EV / Revenue
|
5.9
x
|
6.88
x
|
6.18
x
|
5.62
x
|
4.19
x
|
5.28
x
|
4.97
x
|
4.5
x
|
EV / EBITDA
|
16.4
x
|
18.5
x
|
15
x
|
14.8
x
|
11.1
x
|
13.6
x
|
12.8
x
|
11.4
x
|
EV / FCF
|
25.9
x
|
24.4
x
|
23.1
x
|
23.4
x
|
14.9
x
|
19.5
x
|
18.2
x
|
16.9
x
|
FCF Yield
|
3.86%
|
4.1%
|
4.33%
|
4.27%
|
6.73%
|
5.12%
|
5.48%
|
5.93%
|
Price to Book
|
6.19
x
|
7.44
x
|
7.47
x
|
6.46
x
|
4.65
x
|
6.07
x
|
5.84
x
|
5.59
x
|
Nbr of stocks (in thousands)
|
2,99,95,964
|
2,99,95,964
|
2,99,97,475
|
3,00,00,000
|
3,00,00,000
|
3,00,00,000
|
-
|
-
|
Reference price
3 |
632.7
|
798.9
|
865.0
|
755.0
|
525.0
|
725.0
|
725.0
|
725.0
|
Announcement Date
|
18/02/20
|
08/02/21
|
07/02/22
|
10/02/23
|
19/02/24
|
-
|
-
|
-
|
1IDR in Million2IDR in Billions3IDR Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3,067
|
3,335
|
4,021
|
3,866
|
3,566
|
3,936
|
4,169
|
4,578
|
EBITDA
1 |
1,105
|
1,243
|
1,654
|
1,470
|
1,347
|
1,528
|
1,619
|
1,804
|
EBIT
1 |
1,018
|
1,146
|
1,560
|
1,375
|
1,244
|
1,439
|
1,528
|
1,724
|
Operating Margin
|
33.17%
|
34.35%
|
38.8%
|
35.56%
|
34.88%
|
36.56%
|
36.65%
|
37.65%
|
Earnings before Tax (EBT)
1 |
1,074
|
1,200
|
1,613
|
1,420
|
1,220
|
1,456
|
1,541
|
1,699
|
Net income
1 |
807.7
|
934
|
1,261
|
1,105
|
950.6
|
1,132
|
1,183
|
1,298
|
Net margin
|
26.33%
|
28%
|
31.36%
|
28.58%
|
26.66%
|
28.76%
|
28.37%
|
28.35%
|
EPS
2 |
26.94
|
31.14
|
42.28
|
36.82
|
31.69
|
37.52
|
38.81
|
43.20
|
Free Cash Flow
3 |
6,99,564
|
9,40,615
|
10,76,764
|
9,28,734
|
10,05,007
|
10,63,000
|
11,35,833
|
12,20,667
|
FCF margin
|
22,806.16%
|
28,200.87%
|
26,778.65%
|
24,026.09%
|
28,183.59%
|
27,008.27%
|
27,244.02%
|
26,664.22%
|
FCF Conversion (EBITDA)
|
63,335.27%
|
75,693.06%
|
65,101.71%
|
63,173.55%
|
74,586.95%
|
69,586.97%
|
70,165.23%
|
67,651.05%
|
FCF Conversion (Net income)
|
86,613.04%
|
1,00,706.52%
|
85,396.6%
|
84,070.09%
|
1,05,718.1%
|
93,918.62%
|
96,020.52%
|
94,069.03%
|
Dividend per Share
2 |
24.31
|
31.16
|
34.20
|
-
|
-
|
32.85
|
36.66
|
40.66
|
Announcement Date
|
18/02/20
|
08/02/21
|
07/02/22
|
10/02/23
|
19/02/24
|
-
|
-
|
-
|
1IDR in Billions2IDR3IDR in Million Fiscal Period: December |
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
|
1,655
|
1,245
|
880.5
|
731.6
|
1,612
|
1,002
|
1,252
|
907.3
|
746.5
|
707.5
|
1,205
|
1,053
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
517.5
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
498.2
|
354.1
|
185.2
|
539.4
|
342.4
|
493
|
362.3
|
210.1
|
165.2
|
506.1
|
491.6
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
40.03%
|
40.22%
|
25.32%
|
33.46%
|
34.18%
|
39.38%
|
39.93%
|
28.14%
|
23.35%
|
42.01%
|
46.67%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
464.6
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
502
|
-
|
-
|
150.6
|
445.6
|
-
|
-
|
-
|
-
|
-
|
364.1
|
390.5
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
30.34%
|
-
|
-
|
20.58%
|
27.64%
|
-
|
-
|
-
|
-
|
-
|
30.22%
|
37.07%
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
13.21
|
9.830
|
5.020
|
-
|
9.160
|
12.81
|
10.01
|
4.930
|
4.610
|
12.14
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
1 |
-
|
18.90
|
-
|
13.50
|
-
|
-
|
-
|
-
|
23.00
|
-
|
-
|
-
|
11.49
|
-
|
15.18
|
-
|
12.43
|
Announcement Date
|
27/07/21
|
07/02/22
|
22/04/22
|
29/07/22
|
29/07/22
|
26/10/22
|
10/02/23
|
28/04/23
|
26/07/23
|
30/10/23
|
19/02/24
|
25/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
865
|
1,025
|
1,080
|
923
|
821
|
978
|
1,037
|
1,153
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
2 |
6,99,564
|
9,40,615
|
10,76,764
|
9,28,734
|
10,05,007
|
10,63,000
|
11,35,833
|
12,20,667
|
ROE (net income / shareholders' equity)
|
27.1%
|
29.7%
|
37.7%
|
31.7%
|
27.6%
|
31.8%
|
33.2%
|
35.5%
|
ROA (Net income/ Total Assets)
|
23.5%
|
25.3%
|
31.8%
|
27.1%
|
23.8%
|
29%
|
28.8%
|
30.3%
|
Assets
1 |
3,437
|
3,690
|
3,959
|
4,075
|
3,986
|
3,906
|
4,103
|
4,281
|
Book Value Per Share
3 |
102.0
|
107.0
|
116.0
|
117.0
|
113.0
|
120.0
|
124.0
|
130.0
|
Cash Flow per Share
3 |
27.90
|
34.50
|
40.20
|
36.90
|
35.20
|
44.00
|
47.90
|
52.50
|
Capex
1 |
137
|
95.1
|
123
|
178
|
50.4
|
149
|
162
|
151
|
Capex / Sales
|
4.48%
|
2.85%
|
3.05%
|
4.62%
|
1.41%
|
3.79%
|
3.88%
|
3.29%
|
Announcement Date
|
18/02/20
|
08/02/21
|
07/02/22
|
10/02/23
|
19/02/24
|
-
|
-
|
-
|
1IDR in Billions2IDR in Million3IDR Average target price
710.3
IDR Spread / Average Target -2.03% Consensus |
1st Jan change
|
Capi.
|
---|
| +38.10% | 1.3B | | +37.08% | 5.92B | | -17.43% | 4.51B | | -9.46% | 3.15B | | +0.51% | 3.1B | | -3.53% | 2.42B | | +41.15% | 1.97B | | -5.15% | 1.68B | | +0.09% | 1.65B | | -10.38% | 1.53B |
Alternative Medicine
|